These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 15589593)
41. [Profiling of serum tumor markers in patients with epithelial ovarian carcinoma]. Dong L; Li XP; Cui H; Wang JL; Wei LH; Zhao Y; Wang SJ; Wang Y; Sun XL; Liang XD; Li Y Zhonghua Fu Chan Ke Za Zhi; 2009 Feb; 44(2):121-5. PubMed ID: 19570423 [TBL] [Abstract][Full Text] [Related]
42. [Comparison of therapeutic efficacy between TP regimen and CBP regimen on epithelial ovarian cancer after optimal cytoreductive operation]. Gao KF; Liu FY; Chen FJ; Feng YL Ai Zheng; 2007 Apr; 26(4):431-4. PubMed ID: 17430668 [TBL] [Abstract][Full Text] [Related]
43. [Classification tree analysis in serous ovarian adenocarcinoma patients for prognostic factors associated with three-year survival probability]. Zhu HL; Li Y; Zhao YM; Cui H; Zhao Y; Chang XH; Feng J; Wei LH Zhonghua Fu Chan Ke Za Zhi; 2008 Mar; 43(3):201-4. PubMed ID: 18788570 [TBL] [Abstract][Full Text] [Related]
44. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study. Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC; Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296 [TBL] [Abstract][Full Text] [Related]
45. Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer. Borgoño CA; Kishi T; Scorilas A; Harbeck N; Dorn J; Schmalfeldt B; Schmitt M; Diamandis EP Clin Cancer Res; 2006 Mar; 12(5):1487-93. PubMed ID: 16533772 [TBL] [Abstract][Full Text] [Related]
46. Carboxyterminal telopeptide of type I collagen (ICTP) in predicting prognosis in epithelial ovarian cancer. Simojoki M; Santala M; Risteli J; Kauppila A Gynecol Oncol; 2001 Jul; 82(1):110-5. PubMed ID: 11426971 [TBL] [Abstract][Full Text] [Related]
47. Interaction between preoperative CA-125 level and survival benefit of neoadjuvant chemotherapy in advanced epithelial ovarian cancer. Kang S; Kim TJ; Seo SS; Kim BG; Bae DS; Park SY Gynecol Oncol; 2011 Jan; 120(1):18-22. PubMed ID: 21035174 [TBL] [Abstract][Full Text] [Related]
48. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent. Silva EG; Gershenson DM; Malpica A; Deavers M Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075 [TBL] [Abstract][Full Text] [Related]
49. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gershenson DM; Sun CC; Bodurka D; Coleman RL; Lu KH; Sood AK; Deavers M; Malpica AL; Kavanagh JJ Gynecol Oncol; 2009 Jul; 114(1):48-52. PubMed ID: 19361839 [TBL] [Abstract][Full Text] [Related]
50. [Clinical characteristics of clear cell carcinoma of the ovary]. Shi M; Zhang Y; Shen K; Lang J; Huang H; Wu M Zhonghua Fu Chan Ke Za Zhi; 2002 Mar; 37(3):161-3. PubMed ID: 11953086 [TBL] [Abstract][Full Text] [Related]
51. Human leucocyte antigen (HLA) A2 as a negative clinical prognostic factor in patients with advanced ovarian cancer. Gamzatova Z; Villabona L; Dahlgren L; Dalianis T; Nillson B; Bergfeldt K; Masucci GV Gynecol Oncol; 2006 Oct; 103(1):145-50. PubMed ID: 16542716 [TBL] [Abstract][Full Text] [Related]
52. For women receiving chemotherapy for clinically apparent early ovarian cancer, is there a benefit to surgical staging? Dizon DS; Restivo A; Lomme M; Charbonneau N; Brard L; Hughes T; Weitzen S; Legare R; Granai CO; Disilvestro P Am J Clin Oncol; 2008 Feb; 31(1):39-42. PubMed ID: 18376226 [TBL] [Abstract][Full Text] [Related]
53. Effect of retroperitoneal lymphadenectomy on prognosis of patients with epithelial ovarian cancer. Wang Z; Xiong Z; Wang S Chin Med J (Engl); 2003 Apr; 116(4):588-92. PubMed ID: 12875728 [TBL] [Abstract][Full Text] [Related]
54. [Clinical analysis of prognostic factors for stage III ovarian epithelial carcinoma]. Wu M; Shen K; Lang JH; Huang RL; Huang HF; Pan LY Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(20):1406-9. PubMed ID: 16029654 [TBL] [Abstract][Full Text] [Related]
55. COX-2 and preoperative CA-125 level are strongly correlated with survival and clinical responsiveness to chemotherapy in ovarian cancer. Raspollini MR; Amunni G; Villanucci A; Boddi V; Taddei GL Acta Obstet Gynecol Scand; 2006; 85(4):493-8. PubMed ID: 16612714 [TBL] [Abstract][Full Text] [Related]
56. [Clinical and pathological features of borderline ovarian tumors]. Li Y; Cui H; Shen DH; Zhao Y; Wei LH; Qian HN Zhonghua Fu Chan Ke Za Zhi; 2003 Feb; 38(2):81-4. PubMed ID: 12783693 [TBL] [Abstract][Full Text] [Related]
57. Clinical Significance of CA125 Level after the First Cycle of Chemotherapy on Survival of Patients with Advanced Ovarian Cancer. Lee M; Chang MY; Yoo H; Lee KE; Chay DB; Cho H; Kim S; Kim YT; Kim JH Yonsei Med J; 2016 May; 57(3):580-7. PubMed ID: 26996555 [TBL] [Abstract][Full Text] [Related]
58. Clinical efficacy of modified preoperative neoadjuvant chemotherapy in the treatment of locally advanced (stage IB2 to IIB) cervical cancer: randomized study. Chen H; Liang C; Zhang L; Huang S; Wu X Gynecol Oncol; 2008 Sep; 110(3):308-15. PubMed ID: 18606439 [TBL] [Abstract][Full Text] [Related]
59. CA-125 AUC as a new prognostic factor for patients with ovarian cancer. Mano A; Falcão A; Godinho I; Santos J; Leitão F; Oliveira C; Caramona M Gynecol Oncol; 2005 May; 97(2):529-34. PubMed ID: 15863156 [TBL] [Abstract][Full Text] [Related]
60. Impact of Preoperative Serum Levels of CA 125 on Epithelial Ovarian Cancer Survival. Pradjatmo H; Pradjatmo H Asian Pac J Cancer Prev; 2016; 17(4):1881-6. PubMed ID: 27221870 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]